Syn­er­gy CEO pass­es torch to CCO Troy Hamil­ton; Pres­i­dent Steven Kaf­ka re­signs from Foun­da­tion; Ab­b­Vie vet John Leonard to helm In­tel­lia

Troy Hamil­ton

→ Mark­ing a new phase for the biotech, Syn­er­gy Phar­ma­ceu­ti­cals $SYGP an­nounced that co-founder and Tru­lance co-in­ven­tor Gary Ja­cob is pass­ing the CEO ba­ton to Troy Hamil­ton. Join­ing Syn­er­gy in 2015, Hamil­ton was chief com­mer­cial of­fi­cer and EVP, steer­ing the launch and com­mer­cial­iza­tion of Tru­lance. The chron­ic id­io­path­ic con­sti­pa­tion drug is right up Hamil­ton’s al­ley, as he man­aged the gas­troin­testi­nal unit at Shire for nine years af­ter spend­ing much of his ca­reer at Janssen and Mc­Neil Spe­cial­ty Prod­ucts. “One of my ini­tial ar­eas of fo­cus will be to work with our CFO, Gary Gemignani, and the Syn­er­gy man­age­ment team to con­tin­ue to re­fine our busi­ness plan and fo­cus on achiev­ing cost ef­fi­cien­cies through­out the com­pa­ny while pri­or­i­tiz­ing in­vest­ments that will dri­ve sig­nif­i­cant Tru­lance growth,” Hamil­ton said in the state­ment. He al­so made sure to thank Ja­cob, who will con­tin­ue his in­volve­ment with the com­pa­ny as ex­ec­u­tive chair­man of the board.

Steven Kaf­ka

→ Pres­i­dent and COO Steven Kaf­ka has in­formed Foun­da­tion Med­i­cine $FMI of his in­ten­tion to re­sign next Feb­ru­ary, trig­ger­ing a lead­er­ship reshuf­fle that adds the pres­i­dent ti­tle to CEO Troy Cox and COO role to SVP of in­ter­na­tion­al mar­kets Kon­stan­tin Fiedler. Kaf­ka’s tenure at Foun­da­tion last­ed al­most five years, no­tice­ably longer than his stints at oth­er biotechs in­clud­ing Mil­len­ni­um Phar­ma­ceu­ti­cals and Aileron Ther­a­peu­tics. Cox and Fiedler are both rel­a­tive­ly new to the biotech, but each had spent time at some big name com­pa­nies be­fore land­ing here.

→ Cam­bridge, MA-based start­up Dis­arm Ther­a­peu­tics has lured Pe­ter Keller to join as chief busi­ness of­fi­cer af­ter sev­en years at Se­lec­ta Bio­sciences. Keller hasn’t al­ways worked in biotech — he was a man­age­ment con­sul­tant for a decade — but while in the in­dus­try, he has been in­volved in an ac­qui­si­tion, a big IPO and a bil­lion-dol­lar deal. While we haven’t heard much about where Dis­arm’s ax­on­al de­gen­er­a­tion-pre­vent­ing tech is head­ed, we now know Keller will be shap­ing part of it.

Joe Jimenez

→ As Joe Jimenez con­tin­ues to search for his next big break af­ter No­var­tis (ide­al­ly in Sil­i­con Val­ley), he will spend some time in Cincin­nati as a mem­ber of Proc­ter & Gam­ble’s board of di­rec­tors. Con­sumer busi­ness is fa­mil­iar turf for Jimenez, who worked top jobs at Heinz be­fore tak­ing the reins of the Swiss phar­ma gi­ant.

→ In a clear sig­nal that CRISPR/Cas9 play­er In­tel­lia Ther­a­peu­tics is piv­ot­ing to a Phase I, John Leonard, found­ing chief med­ical of­fi­cer, is be­ing kicked up to the CEO’s of­fice. Hav­ing led the biotech $NT­LA through a quick and suc­cess­ful IPO in 2016, At­las part­ner Nes­san Berming­ham will re­turn to biotech ven­ture cap­i­tal. The R&D trek will like­ly be long, with ri­vals Ed­i­tas and CRISPR Ther­a­peu­tics — who are still fight­ing over the IP — de­ter­mined to have a slice of the mar­ket. The board is putting its faith in Leonard, the for­mer top sci­en­tist at Ab­b­Vie who worked on HIV and HCV while tak­ing a lead role on Hu­mi­ra dur­ing his 22-year tenure.

Gen­zyme vet Marc Beck­er will be Con­cert Phar­ma’s new CFO, af­ter a brief stint at CRISPR Ther­a­peu­tics. The Lex­ing­ton, MA-based biotech $CNCE is prepar­ing to broad­en its pipeline of deu­teri­um chem­istry prod­uct can­di­dates — a pipeline where four out of five pro­grams are cur­rent­ly part­nered — and Beck­er will be very much in­volved in that, ac­cord­ing to a state­ment.

→ Paris-based Ac­ti­cor Biotech has tapped Yan­nick Plé­tan as its first chief med­ical of­fi­cer. A spin­off from the French Na­tion­al In­sti­tute of Health and Med­ical Re­search, the 4-year-old com­pa­ny is de­vel­op­ing an an­tithrom­bot­ic agent for the acute phase of is­chemic stroke. Plé­tan’s clin­i­cal and med­ical ex­pe­ri­ence at Roche and Pfiz­er will be im­por­tant as Ac­ti­cor nav­i­gates the next tri­al phase for its lead can­di­date ACT017.

Ra­jesh Shrotriya, the 15-year chair­man and CEO of Spec­trum Phar­ma­ceu­ti­cals, has been fired, the com­pa­ny an­nounced Sun­day. The ter­mi­na­tion trig­gered a chain of lead­er­ship changes: cur­rent pres­i­dent and COO Joseph Tur­geon is now pres­i­dent and CEO, as well as a board of di­rec­tor mem­ber; di­rec­tor Stu­art Krass­ner fills the chair­man seat; and Thomas Riga (EVP, CCO and head of busi­ness de­vel­op­ment) be­comes COO. Tur­geon is an Am­gen vet who used to over­see com­mer­cial ac­tiv­i­ties for Spec­trum.

→ For­est Labs vet Charles Ryan will take the CEO’s job at Neu­rotrope $NTRP fol­low­ing the res­ig­na­tion of Su­sanne Wilke.

→ In line with CEO George Scan­gos’ vi­sion for Vir Biotech­nol­o­gy to be a sci­ence-dri­ven com­pa­ny, im­mu­nol­o­gist An­to­nio Lan­za­vec­chia has been brought on as SVP and se­nior re­search fel­low. His main charge is to pro­vide sci­en­tif­ic lead­er­ship for Vir’s tech­ni­cal pro­grams look­ing in­to se­ri­ous in­fec­tious dis­eases. While do­ing that for the San Fran­cis­co up­start, he will con­tin­ue his roles as di­rec­tor of the In­sti­tute for Re­search in Bio­med­i­cine in Bellinzona, Switzer­land and as pro­fes­sor at the Uni­ver­sità del­la Svizzera ital­iana.

→ Fol­low­ing No­vem­ber’s IPO, Apel­lis Phar­ma­ceu­ti­cals $APLS has ap­point­ed Tim­o­thy Sul­li­van, for­mer­ly a VC firm part­ner, as CFO. Sul­li­van has spent the past three years as an ob­serv­er on Apel­lis’ board of di­rec­tors, as the Ken­tucky biotech took its Soliris ri­val drug and age-re­lat­ed mac­u­lar de­gen­er­a­tion ther­a­py fur­ther along the pipeline, rais­ing mon­ey even af­ter a foiled first IPO at­tempt. Now Apel­lis is ready to en­ter Phase III tri­als for both pro­grams in 2018, and in his new role, Sul­li­van will lead the de­vel­op­ment of its fi­nanc­ing and growth strat­e­gy.

→ Long­time EVP and CFO Ryan May­nard is re­sign­ing from South San Fran­cis­co-based Rigel Phar­ma­ceu­ti­cals $RIGL for undis­closed rea­sons (but cer­tain­ly not due to a dis­pute or dis­agree­ment with the com­pa­ny, ac­cord­ing the to SEC fil­ing). Nel­son Ca­bat­u­an, cur­rent VP of fi­nance, will step in as the in­ter­im prin­ci­pal ac­count­ing of­fi­cer while the biotech search­es for a re­place­ment ahead of its lead drug’s PDU­FA date.

Bellerophon Ther­a­peu­tics $BLPH has qui­et­ly hired a new CFO, As­saf Ko­rner, to re­place Megan Schoeps, who re­signed a cou­ple weeks ago. Ko­rner has worked a slate of fi­nan­cial jobs at med­ical de­vice and con­sumer prod­uct com­pa­nies such as Syneron Med­ical, Ilu­mi­nage Beau­ty and KP­MG.

→ Af­ter wow­ing in­vestors with its BC­MA-tar­get­ing CAR-T at ASH, blue­bird bio $BLUE turned to its in­ter­nal op­er­a­tions and named Ko­ry Went­worth VP of fi­nance and prin­ci­pal ac­count­ing of­fi­cer. A vet­er­an of big pub­lic ac­count­ing firms, Went­worth cut his teeth in biotech con­troller­ship dur­ing his 9-year run at Alex­ion. He fills the shoes of Jef­frey Walsh, the biotech’s chief fi­nan­cial and strat­e­gy of­fi­cer, who will con­tin­ue to serve in the prin­ci­pal fi­nan­cial role.

→ British dis­cov­ery and de­vel­op­ment ser­vice provider Con­cept Life Sci­ences has hired An­drew Scott as head of bioas­say de­vel­op­ment and screen­ing, and Ma­g­a­lie Fer­bach as busi­ness de­vel­op­ment di­rec­tor for South­ern and Cen­tral Eu­rope. Scott has ex­pe­ri­ence span­ning phar­ma, biotech and CRO, while Fer­bach’s back­ground is in agro­chem­i­cals. These ap­point­ments wrap up Con­cept’s ex­pand­ing year, marked by the ac­qui­si­tion of Aquila Bio­med­ical in Ed­in­burgh and open­ing of new lab­o­ra­to­ry space at Alder­ly Park.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als due to missed pri­ma­ry end­point

Roche has terminated one of two Phase II trials testing its drug ralmitaront in patients with schizophrenia, the Big Pharma confirmed to Endpoints News.

The study was terminated last month, according to a June 22 update to the registry on clinicaltrials.gov. Begun in September 2020, the trial was looking at ralmitaront in patients with acute schizophrenia. The trial enrolled 286 patients out of an originally planned 308.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pearl Huang, Dunad Therapeutics CEO (Ken Richardson, PR Newswire)

Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

It has only been a few months since Pearl Huang exited the top seat at Cygnal Therapeutics, but now she’s back at the helm of another biotech.

After taking a few months off — passing an exam in that time to get her captain’s license from the US Coast Guard — she’s been named CEO of Dunad Therapeutics, a biotech focused on developing a small molecule covalent therapies that was founded in 2020. Huang told Endpoints News that two factors attracted her to going back to the c-suite: the company’s technology and its co-founders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Years af­ter link­ing arms with Bris­tol My­ers and both Mer­cks, Sutro finds its lat­est part­ner in Tokyo

Astellas and Sutro Biopharma are linking arms on a new field of antibody-drug conjugates that they hope will improve upon existing cancer immunotherapies.

The Tokyo pharma will dole out $90 million in cash for the collaboration, the companies said Monday afternoon. That upfront payment will extend the South San Francisco biotech’s runway from late 2023 into the first half of 2024, Cowen analysts noted.

Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

Roivant is sweeping a suite of drugs, including a gene therapy for sickle cell disease already in the clinic, out of its pipeline.

Six programs from four of its “vants” are being wound down as part of “a company-wide cost optimization and pipeline reprioritization initiative to reduce our expected operating expenses and prioritize our capital resources.”

When reached by Endpoints News, a spokesperson said, “We don’t anticipate a material reduction in headcount but we will likely reassign some folks to higher value projects as part of winding down specific programs.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Laurence Reid, Decibel CEO

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

Though Decibel Therapeutics has largely pivoted toward gene therapies for the inner ear, its lead clinical candidate simply aims to protect cancer patients from chemotherapy-induced hearing loss. On Tuesday, the biotech presented its first efficacy data for the program, and execs like what they see.

Decibel reported interim results from a Phase Ib study showing the experimental drug, dubbed DB-020, largely protected a small group of patients from losing their hearing. Researchers used a particularly unique study design, administering the compound in one of each patients’ ears before they received cisplatin chemotherapy and placebo in the other.

Ben Zimmer, Priovant CEO

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

In November, Pfizer disclosed it’s spun out the Phase II dual JAK1/TYK2 inhibitor to a startup formed in collaboration with an unnamed, experienced partner.

We now know who the partner is. And as Pfizer and Roivant officially take the wraps off Priovant Therapeutics, the companies reveal that they have started two registrational trials of the drug, brepocitinib, as part of a broader plan to develop a big, first-in-class franchise spanning multiple orphan and specialty autoimmune diseases.